ARTICLE | Clinical News
Aeterna files to begin Phase III
February 1, 2000 8:00 AM UTC
Aeterna (TSE:AEL) filed to begin a 270-patient placebo-controlled Phase III study in the U.S., Canada and Europe of its Neovastat oral angiogenesis inhibitor to treat progressive kidney cancer. ...